Overview

The 'KLOW' protocol is a four-peptide blend -- essentially the GLOW stack with KPV added (the leading K denotes KPV):

• BPC-157 -- pentadecapeptide that accelerates soft-tissue and gut healing, largely via VEGF-driven angiogenesis (Chang et al., 2019; Brcic et al., 2009).
• TB-500 -- thymosin beta-4 fragment that promotes cell migration, angiogenesis and wound repair (Philp et al., 2004).
• GHK-Cu -- copper tripeptide that stimulates collagen, elastin and glycosaminoglycan synthesis and skin remodeling (Pickart, 2008).
• KPV -- the tripeptide Lys-Pro-Val, the C-terminal fragment of alpha-melanocyte-stimulating hormone, with anti-inflammatory activity. It is transported into cells via PepT1 and suppresses NF-kB-driven inflammation independent of melanocortin receptors, reducing intestinal and tissue inflammation in models (Dalmasso et al., 2008).

The added rationale over GLOW is an explicit anti-inflammatory arm: KPV is intended to calm the inflammatory environment while the other three peptides drive vascularisation, cell recruitment and matrix rebuilding.

Typical stack dosing (research-community practice, not clinically validated): often a once-daily subcutaneous injection providing roughly BPC-157 250-500 mcg, TB-500 250-500 mcg, GHK-Cu 1-2 mg and KPV 250-500 mcg, run in multi-week cycles. KPV is also used orally for gut-directed effects given its PepT1-mediated uptake. These figures derive from the individual peptides' preclinical literature and community protocols; none of the components is FDA-approved and the blend has no controlled human trial data.

Mechanism of Action

The three regenerative peptides supply vascularisation (BPC-157 via VEGF/NO; TB-500 via actin-driven endothelial migration) and extracellular-matrix rebuilding (GHK-Cu). KPV adds transporter-mediated intracellular anti-inflammatory signalling: accumulating in epithelial and immune cells through PepT1, it suppresses NF-kB and reduces neutrophil infiltration and cytokine expression, an effect shown for intestinal inflammation and proposed to benefit gut- and skin-directed uses of the stack.

Reconstitution Calculator

Safety Profile

Safety Profile: KLOW Protocol

Common Side Effects

• Individual component side effects: the KLOW protocol combines multiple peptides and compounds; side effects reflect the additive profile of each constituent
• Injection site reactions: redness, swelling, pain, and itching at subcutaneous injection sites
• Fatigue and flu-like symptoms, particularly during initial protocol phases
• Headache and mild gastrointestinal discomfort (nausea, bloating)
• Water retention and transient edema
• Sleep disturbances (insomnia or excessive drowsiness depending on components)

Serious Adverse Effects

• Compounded hormonal disruption: multi-peptide protocols may unpredictably alter hormonal axes (GH/IGF-1, hypothalamic-pituitary-gonadal, thyroid)
• Immunological reactions: risk increases with multiple injectable peptides; includes severe allergic reactions and antibody formation against peptide components
• Cardiovascular risk: cumulative effects of multiple growth-promoting peptides may increase cardiac hypertrophy risk and insulin resistance
• Tumor promotion: theoretical concern that stacking growth factor–stimulating peptides may promote growth of undiagnosed malignancies
• No peer-reviewed clinical trials exist for the combined KLOW protocol; all safety inferences are extrapolated from individual component data

Contraindications

• Active malignancy or history of cancer (growth-promoting peptides may stimulate tumor growth)
• Uncontrolled diabetes or insulin resistance (multiple components may worsen glycemic control)
• Cardiovascular disease including heart failure, uncontrolled hypertension, or history of cardiac hypertrophy
• Pregnancy or lactation (multi-peptide hormonal effects are unpredictable)
• Autoimmune conditions (immune-modulating peptides may trigger flares)
• Hepatic or renal impairment (clearance of multiple peptides may be compromised)

Drug Interactions

• Insulin and oral hypoglycemics: growth hormone–stimulating components may antagonize glucose control
• Anticoagulants: some peptide components may affect coagulation parameters
• Immunosuppressants: immune-modulating peptides may counteract immunosuppressive therapy
• Thyroid medications: protocol components may alter thyroid hormone metabolism
• Corticosteroids: may blunt efficacy of growth hormone–releasing peptides
• Complex polypharmacy risk: interactions between protocol components themselves are poorly characterized

Population-Specific Considerations

• Pregnancy/Lactation: strictly contraindicated; hormonal effects of stacked peptides are unpredictable and potentially teratogenic
• Children/Adolescents: not appropriate; developing endocrine systems are vulnerable to multi-axis hormonal manipulation
• Elderly: increased cardiovascular and metabolic risk; multi-peptide protocols require careful cardiac and metabolic monitoring
• Athletes: many components may be prohibited by WADA and sports anti-doping agencies
• General: this is a non-FDA-approved stacking protocol; medical supervision is essential; no standardized dosing or safety monitoring guidelines exist

Pharmacokinetic Profile